Direct-acting antiviral agents for treating chronic hepatitis C

Published on 04 Jun 2024
Last Updated on 04 Jun 2024

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Sofosbuvir 400 mg/velpatasvir 100 mg tablets

in line with its registered indications for treating chronic hepatitis C.

Funding status

Sofosbuvir 400 mg/velpatasvir 100 mg tablet is recommended for inclusion on the Standard Drug List (SDL) from 1 August 2024.

Of note, glecaprevir 100 mg/pibrentasvir 40 mg tablet will be delisted from the MOH List of Subsidised Drugs with effect from 1 February 2025.

Direct-acting antiviral agents for treating chronic hepatitis C (Published 4 Jun 24) [PDF, 100 KB]